Saniona
A rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | €500k | Post IPO Equity | |
| Total Funding | 000k | ||
| SEK | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 208 % | 28 % | 46 % | 10 % | 1887 % | (38 %) | 1349 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1976 %) | (3849 %) | (1425 %) | (487 %) | 76 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (896 %) | (3922 %) | (1605 %) | (569 %) | 56 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Saniona is a biopharmaceutical company focused on discovering and developing innovative treatments for rare diseases, particularly those related to neuropathic pain, itching disorders, and obesity-related conditions. The company operates in the healthcare and biotechnology market, targeting patients with unmet medical needs. Saniona's business model revolves around advancing its proprietary pipeline of drug candidates through preclinical and clinical stages, with a focus on conditions such as Prader-Willi Syndrome, hypothalamic obesity, and rare inflammatory disorders. Revenue is generated through partnerships, licensing agreements, and direct sales of its developed therapies. The company has successfully raised significant capital to support its research and development efforts, including a recent USD 65 million directed issue of shares. Saniona serves a niche market of patients with rare and often debilitating conditions, aiming to provide effective and life-changing treatments.
Keywords: biopharmaceutical, rare diseases, neuropathic pain, itching disorders, obesity, Prader-Willi Syndrome, hypothalamic obesity, inflammatory disorders, drug development, clinical trials.
